prodchem
Aug 20, 2026
C&EN's August 18 Business Watch highlighted two very different developments that illustrate the breadth of current chemical and pharmaceutical industry activity: BASF's historic workforce milestone at Ludwigshafen and the launch of biotech company Khartis Therapeutics.
One story reflects industrial contraction and restructuring in Europe, while the other points toward new pharmaceutical innovation and biotech investment. Together, they provide a useful snapshot of the themes attracting attention across the chemical and pharmaceutical sectors in 2026.
The two developments represent opposite sides of the industry.
BASF's Ludwigshafen milestone raises questions about:
European chemical competitiveness
Energy and feedstock costs
Industrial restructuring
Manufacturing efficiency
Long-term employment trends
Khartis, meanwhile, represents:
Biotech innovation
New drug-development platforms
Oral small-molecule therapies
Venture-backed pharmaceutical research
Future pipeline opportunities
Tracking both provides a broader view of where the industry is heading.
BASF CEO Markus Kamieth noted that the number of full-time-equivalent employees at Ludwigshafen fell below 30,000 in May 2026, the first time the figure has been below that level since 1954.
The number is significant because Ludwigshafen is BASF's largest site and a symbol of Germany's chemical manufacturing strength.
The milestone therefore represents more than a workforce statistic.
It highlights the scale of restructuring occurring within one of Europe's most important chemical production centers.
The Ludwigshafen development reflects several pressures facing European chemical producers.
These include:
High energy prices
Expensive feedstocks
Weak industrial demand
Global competition
Underutilized production capacity
C&EN linked the workforce milestone to broader concerns about European industrial competitiveness and deindustrialization.
Workforce reductions do not mean that BASF is abandoning the site.
Ludwigshafen remains a major integrated chemical complex and continues to receive investment in technologies and production capabilities.
For example, BASF started up a production plant for 3D-printed catalysts at Ludwigshafen in 2026, demonstrating that restructuring is occurring alongside technology investment.
This suggests a more complicated strategy:
Fewer employees + More efficient assets + Higher-value technology
rather than simple industrial withdrawal.
While BASF's story focuses on contraction, Khartis Therapeutics represents expansion into a new generation of pharmaceutical development.
The company launched with a focus on developing oral small-molecule medicines, including an oral selective IGF-1R inhibitor for thyroid eye disease.
Its strategy reflects a growing biotech interest in developing more convenient alternatives to established injectable therapies.
The pharmaceutical industry is increasingly looking beyond simply discovering new biological targets.
Companies are also attempting to improve:
Drug delivery
Patient convenience
Treatment accessibility
Dosing flexibility
Long-term adherence
An oral therapy can potentially offer significant advantages over treatments requiring clinical administration, provided it can deliver comparable efficacy and safety.
At first glance, BASF and Khartis have little in common.
One is a major industrial chemical producer restructuring a historic manufacturing site.
The other is a young biotech company building a new pharmaceutical pipeline.
But both demonstrate how the industrial landscape is changing.
BASF → optimizing established industrial infrastructure
Khartis → developing new pharmaceutical platforms
The contrast illustrates how capital and innovation are moving toward different opportunities across the broader chemicals and life-sciences ecosystem.
C&EN's same Business Watch also highlighted several other developments, including Covestro's force majeure caused by low Rhine water levels. The disruption affected propylene oxide availability at its Dormagen site and followed a similar BASF force majeure involving surfactants.
This adds another major theme to the week's business landscape:
Infrastructure and climate-related disruption are becoming operational risks for chemical producers.
The Rhine disruption demonstrates how chemical production depends on infrastructure far beyond the factory gate.
Low water levels can affect:
Raw-material deliveries
Finished-product shipments
Production schedules
Inventory requirements
Customer commitments
C&EN reported that more than 30% of Covestro's finished materials and 75% of its European raw materials move on waterways.
For procurement teams, these figures underline the importance of geographic and logistics diversification.
Despite European cost pressures, companies continue investing in technologies designed to improve competitiveness.
BASF's 3D-printed catalyst facility at Ludwigshafen is one example. The technology is designed to improve reactor efficiency while reducing energy consumption.
This suggests that European chemical companies are not simply responding to pressure through closures and workforce reductions.
They are also looking for ways to make remaining assets more productive.
The week's stories highlight several intelligence signals procurement professionals should monitor:
Plant closures
Workforce reductions
Force majeure declarations
Rhine and other logistics disruptions
New production technologies
Biotech financing
Pharmaceutical pipeline launches
Supplier consolidation
These developments can provide early warnings about future availability, pricing and sourcing conditions.
For investors, the stories reveal two different types of opportunity.
In chemicals:
Can restructuring restore competitiveness?
In pharmaceuticals:
Can emerging platforms translate scientific innovation into commercial products?
The answers will determine where capital continues to flow.
The August 18 Business Watch provides a useful snapshot of an industry moving in several directions simultaneously.
BASF's sub-30,000 Ludwigshafen workforce highlights the pressure facing Europe's traditional chemical manufacturing model.
Khartis's launch represents the continuing search for new pharmaceutical technologies and more convenient drug-delivery approaches.
Meanwhile, Rhine disruptions demonstrate that climate and infrastructure risks are becoming increasingly relevant to chemical supply chains.
Together, these stories show why chemical and pharmaceutical market intelligence cannot focus on one metric alone.
Manufacturing capacity, workforce trends, technology investment, logistics resilience and biotech innovation are all shaping the industry's next phase.
C&EN's August 18 Business Watch highlighted BASF's Ludwigshafen workforce milestone and Khartis Therapeutics' launch among the week's notable industry stories.
BASF's Ludwigshafen workforce fell below 30,000 employees in May 2026 for the first time since 1954.
The milestone reflects broader pressure on European chemical manufacturing competitiveness.
BASF continues investing in technology at Ludwigshafen, including 3D-printed catalyst production.
Khartis represents the opposite trend, focusing on new pharmaceutical innovation and oral small-molecule development.
Rhine water levels are creating additional supply-chain risks for European chemical producers.
Procurement teams should monitor restructuring, logistics disruptions and emerging pharmaceutical pipelines together.
The week's stories demonstrate the contrast between industrial optimization and next-generation innovation.
Chemical and pharmaceutical market intelligence increasingly requires tracking manufacturing, technology, logistics and investment trends simultaneously.
Featured Product
Found this useful?
Continue Reading
Growing demand for GLP-1 and related metabolic therapies is increasing regulatory scrutiny of unauthorized compounding and unapproved peptide products. The retatrutide black market illustrates how rapidly expanding demand can create enforcement challenges across pharmaceutical supply chains
BASF's plant closures at Ludwigshafen highlight the formal regulatory and labor consultation processes involved in large-scale German industrial restructuring. As the site reduces its workforce, the company must navigate employee representation, regulatory requirements and operational transition alongside its capacity adjustments.
Khartis's oral IGF-1R inhibitor candidate could provide a regulatory test case for oral alternatives to established infusion-based therapies. Its development may show how the FDA evaluates convenience, efficacy, safety and clinical comparability when a new oral treatment seeks to displace an established injectable option.
